Abstract:Introduction: The management of anemia in chronic kidney disease (CKD-An) presents significant challenges for nephrologists due to variable responsiveness to erythropoietin-stimulating agents (ESAs), hemoglobin (Hb) cycling, and multiple clinical factors affecting erythropoiesis. The Anemia Control Model (ACM) is a decision support system designed to personalize anemia treatment, which has shown improvements in achieving Hb targets, reducing ESA doses, and maintaining Hb stability. This study aimed to evaluate the association between ACM-guided anemia management with hospitalizations and survival in a large cohort of hemodialysis patients. Methods: This multi-center, retrospective cohort study evaluated adult hemodialysis patients within the European Fresenius Medical Care NephroCare network from 2014 to 2019. Patients treated according to ACM recommendations were compared to those from centers without ACM. Data on demographics, comorbidities, and dialysis treatment were used to compute a propensity score estimating the likelihood of receiving ACM-guided care. The primary endpoint was hospitalizations during follow-up; the secondary endpoint was survival. A 1:1 propensity score-matched design was used to minimize confounding bias. Results: A total of 20,209 eligible patients were considered (reference group: 17,101; ACM adherent group: 3108). Before matching, the mean age was 65.3 ± 14.5 years, with 59.2% men. Propensity score matching resulted in two groups of 1950 patients each. Matched ACM adherent and non-ACM patients showed negligible differences in baseline characteristics. Hospitalization rates were lower in the ACM group both before matching (71.3 vs. 82.6 per 100 person-years, p < 0.001) and after matching (74.3 vs. 86.7 per 100 person-years, p < 0.001). During follow-up, 385 patients died, showing no significant survival benefit for ACM-guided care (hazard ratio = 0.93; p = 0.51). Conclusions: ACM-guided anemia management was associated with a significant reduction in hospitalization risk among hemodialysis patients. These results further support the utility of ACM as a decision-support tool enhancing anemia management in clinical practice.

Data-Driven Modeling and Control of Complex Dynamical Systems Arising in Renal Anemia Therapy

Data Driven Computational Modeling of Hematopoiesis in Myelodysplastic Syndromes Unveils Differences in Hematopoietic Stem Cell Kinetics Compared to Age-Matched Healthy Controls

Data2Dynamics: a Modeling Environment Tailored to Parameter Estimation in Dynamical Systems.

Rapid prototyping of multi-compartment models for urea kinetics in hemodialysis: a System Dynamics approach

Semi-Blind and l1 Robust System Identification for Anemia Management

Mathematical modelling of bicarbonate supplementation and acid-base chemistry in kidney failure patients on hemodialysis

A Quantitative Systems Physiology Model of Renal Function and Blood Pressure Regulation: Model Description

Data-Driven Dynamic Modeling and Online Monitoring for Multiphase and Multimode Batch Processes with Uneven Batch Durations

Evaluating epoetin dosing strategies using observational longitudinal data

Lessons Learned from Quantitative Dynamical Modeling in Systems Biology

Optimization of anemia treatment in hemodialysis patients via reinforcement learning

Systems-level health of patients living with end-stage kidney disease using standard lab values

Development and validation of a chronic kidney disease progression model using patient-level simulations

Optimizing anemia management using artificial intelligence for patients undergoing hemodialysis

An Approach for Personalized Dynamic Assessment of Chronic Kidney Disease Progression Using Joint Model

Usage of the Anemia Control Model Is Associated with Reduced Hospitalization Risk in Hemodialysis

Enhancing Dynamical System Modeling through Interpretable Machine Learning Augmentations: A Case Study in Cathodic Electrophoretic Deposition

A mathematical study of the hematopoiesis process with applications to chronic myelogenous leukemia

Current Status of Renal Anemia Pharmacotherapy-What Can We Offer Today

Allo-Hemodialysis, a Novel Dialytic Treatment Option for Patients with Kidney Failure: Outcomes of Mathematical Modelling, Prototyping, and Ex Vivo Testing

On Estimation and Cross-validation of Dynamic Treatment Regimes with Competing Risks